Last reviewed · How we verify
RDEA3170
At a glance
| Generic name | RDEA3170 |
|---|---|
| Sponsor | Ardea Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria (PHASE2)
- Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia (PHASE2)
- A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA (PHASE2)
- RDEA3170 Tablet and Capsule Bioavailability Study (PHASE1)
- Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects (PHASE2)
- RDEA3170 and Allopurinol Combination Study in Gout Subjects (PHASE1)
- RDEA3170 Bioavailability Study (PHASE1)
- RDEA3170 and Febuxostat Combination Study in Gout Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RDEA3170 CI brief — competitive landscape report
- RDEA3170 updates RSS · CI watch RSS
- Ardea Biosciences, Inc. portfolio CI